Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma

Current Oncology

Volumn 13, Issue 1, 2006, Pages

  Williams, Lara J ^a   Guernsey, Duane L ^a,b   Casson, Allan G ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Barrett esophagus; Biomarkers; Esophageal adenocarcinoma; Molecular pathogenesis

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 20; CYTOKERATIN 7; PROTEIN P16; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

AGE; ANEUPLOIDY; BARRETT ESOPHAGUS; BODY MASS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CARCINOGENESIS; CHROMOSOME 17P; COLUMNAR EPITHELIUM; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; EUROPE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LIFESTYLE; METAPLASIA; NORTH AMERICA; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOCIAL ASPECT; SQUAMOUS EPITHELIUM;

EID: 35348862287     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.
3. Powell J, McConkey CC, Gillison EW, Spychal RT. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422-7.
4. Mayne ST, Navano SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 2002;132(suppl):3467S-70S.
5. Forman D. Oesophago-gastric adenocarcinoma - an epidemiological perspective. Aliment Pharmacol Ther 2004;20:55-60.
6. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54 (suppl 1):i1-5.
7. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10.
8. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
9. 2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11: 231-8.
10. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
11. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11.
12. Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull 1997;53:238-52.
13. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-weight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
14. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104-9.
15. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
16. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
17. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
18. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-32.
19. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-13.
20. Zhang ZF, Kurtz RC, Yu GP, et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 1997; 27:298-309.
21. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000;87:750-4.
22. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1055-62.
23. Zhang ZF, Kurtz RC, Sun M, et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev 1996;5:761-8.
24. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89: 1277-84.
25. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
26. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-42.
27. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
28. Spechler SJ. Columnar-lined esophagus. Definitions. Chest Surg Clin N Am 2002;12:1-13.
29. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
30. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-81.
31. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surg Clin N Am 2002;12:93-111.
32. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369-97.
33. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64: 1561-9.
34. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
35. Antonioli DA, Wang HH. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997;26:495-506.
36. Oberg S, DeMeester TR, Peters JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999;117:572-80.
37. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303-21.
38. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
39. Spechler SJ. Short and ultrashort Barrett's esophagus - what does it mean? Semin Gastrointest Dis 1997;8:59-67.
40. Clark GWB, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-14.
41. Ruol A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520-8.
42. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology 2000;119:683-90.
43. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003;27: 999-1008.
44. Barrett's esophagus: epidemiological and clinical results of a multicentric survey. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Int J Cancer 1991;48: 364-8.
45. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma Gastroenterol Clin North Am 1997;26: 487-94.
46. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epitbelium. Gastroenterology 1992;103:1241-5.
47. Bonelli L. Barrett's esophagus: results of a multicentric survey. GOSPE (Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago). Endoscopy 1993;25:652-4.
48. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol 1996;91:1507-11.
49. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based and autopsy findings. Gastroenterology 1990;99:918-22.
50. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County Minnesota. Gut 2001;48:304-9.
51. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's esophagus: education, enthusiasm, or epidemiology? Lancet 1997;350:933.
52. Caygill CP, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999;11:1355-8.
53. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998;93:1033-6.
54. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
55. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-82.
56. Oberg S, Wenner J, Johansson J, Walther B, Willen R. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005;242:49-54.
57. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
58. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
59. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4.
60. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000;46:9-13.
61. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92:2012-16.
62. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998;85:1457-9.
63. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 Gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
64. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005; 19:15-35.
65. Sampliner RE for the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
66. Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett's oesophagus. Gut 2005;54(suppl 1): i38-42.
67. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
68. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-80.
69. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7.
70. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
71. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
72. Champion G, Richter JE, Vaezi MF, Sihgh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107: 747-54.
73. Goldstein SR, Yang G, Curtis SK, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18: 2265-70.
74. Vaezi MF, Richter JE. Bile reflux in columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:565-82.
75. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-19.
76. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
77. Gillen P, McDermott M, Grehan D, Hourihane DO, Hennessy TP. Proliferating cell nuclear antigen in the assessment of Barrett's mucosa. Br J Surg 1994;81:1766-8.
78. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995;75:423-9.
79. Trudgill N. Familial factors in the etiology of gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma. Chest Surg Clin N Am 2002;12:15-24.
80. McKinley M, Sherlock P. Barrett's esophagus with adenocarcinoma in scleroderma. Am J Gastroenterol 1984;79:438-9.
81. Meyer W, Vollmar F, Bar W. Barrett-esophagus following total gastrectomy. A contribution to its pathogenesis. Endoscopy 1979;11:121-6.
82. Spechler SJ, Schimmel EM, Dalton JW, Doos W, Trier JS. Barrett's epithelium complicating lye ingestion with sparing of the distal esophagus. Gastroenterology 1981;81:580-3.
83. Kortan P, Warren RE, Gardner J, Ginsberg RJ, Diamant NE. Barrett's esophagus in a patient with surgically tested achalasia. J Clin Gastroenterol 1981;3:357-60.
84. Sartori S, Nielsen I, Indelli M, Trevisani L, Pazzi P, Grandi E. Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): an iatrogenic injury? Ann Intern Med 1991;114:210-11.
85. Chalasani N, Wo JM, Hunter JG, Waring JP. Significance of intestinal metaplasia in different areas of esophagus including the esophagogastric junction. Dig Dis Sci 1997;42:603-7.
86. Richter JE. Intestinal metaplasia and the squamocolumnar junction: what does it all mean? Gut 1998;42:604-5.
87. Chen YY, Antonioli DA, Spechler SJ, Zeroogian JM, Goyal RK, Wang HH. Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Mod Pathol 1998;11:950-6.
88. Vaezi MF, Falk GW, Peek RM, et al. CAGA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gcastroenterol 2000;95:2206-11.
89. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93:1054-61.
90. Menke-Pluymers MB, Mulder AH, Hop We, van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's esophagus. The Rotterdam Oesophageal Tumour Study Group. Gut 1994;35: 1348-51.
91. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996;93:7081-4.
92. Montgomery EA, Hartmann DP, Carr NJ, Holterman DA, Sobin LH, Azumi N. Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies. Am J Clin Pathol 1996;106:298-304.
93. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study of a cohort of patients. Cytometry 1998;34:257-63.
94. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:3089-96.
95. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
96. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus, II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
97. Rabinovitch PS, Longton G, Blount PU, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus. III: baseline flow cytometric variables. Am J Gastroenterol 2001;96: 3071-83.
98. Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erb-B2 oncoprotein expression in adenocarcinoma of Barrett's esophagus. Cancer 1994;73:1785-94.
99. Sarbia M, Molsberger G, Willers R, et al. The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction. J Cancer Res Clin Oncol 1996;122: 186-8.
100. Gleeson CM, Sloan JM, McManus DT, et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer 1998;77:277-86.
101. Chanvitan A, Puttawibul P, Casson AG. Flow cytometry in squamous cell esophageal cancer and precancerous lesions. Dis Esophagus 1997;10:206-10.
102. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187: 112-16.
103. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6:44-55.
104. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-5.
105. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;54:64-75.
106. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 Gene mutations in Barrett's epitheliumn and esophageal cancer. Cancer Res 1991;51:4495-9.
107. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996;111: 323-33.
108. Casson AG, Evans SC, Gillis A, et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003;125:1121-31.
109. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221-34.
110. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 1996;5:457-9.
111. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
112. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
113. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-47.
114. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 63:7056-61.
115. Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005;104:730-9.
116. INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-13.
117. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
118. Hardie LJ, Darnton SJ, Wallis YL, et al. p16 Expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005; 217:221-30.